


Pelecopan

| | | | |
|--------------------|--|-------|----------|
| Cat. No.: | HY-147297 | | |
| CAS No.: | 2378380-49-3 | | |
| Molecular Formula: | C ₂₃ H ₁₉ FN ₂ O ₄ | | |
| Molecular Weight: | 406.41 | | |
| Target: | Complement System | | |
| Pathway: | Immunology/Inflammation | | |
| Storage: | Powder | -20°C | 3 years |
| | In solvent | -80°C | 6 months |
| | | -20°C | 1 month |



SOLVENT & SOLUBILITY

| | | | | | | |
|---|--|--------------------------|-------|-----------|------------|------------|
| In Vitro | DMSO : 100 mg/mL (246.06 mM; Need ultrasonic) | | | | | |
| | Preparing Stock Solutions | Solvent Concentration | Mass | 1 mg | 5 mg | 10 mg |
| | | | 1 mM | 2.4606 mL | 12.3028 mL | 24.6057 mL |
| | | | 5 mM | 0.4921 mL | 2.4606 mL | 4.9211 mL |
| | | | 10 mM | 0.2461 mL | 1.2303 mL | 2.4606 mL |
| Please refer to the solubility information to select the appropriate solvent. | | | | | | |
| In Vivo | 1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (6.15 mM); Clear solution | | | | | |
| | 2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (6.15 mM); Clear solution | | | | | |
| | 3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (6.15 mM); Clear solution | | | | | |

BIOLOGICAL ACTIVITY

| | |
|---------------------------|--|
| Description | Pelecopan (BCX9930) is a potent, selective, orally active inhibitor of complement factor D with an IC ₅₀ value of 14.3 nM. Pelecopan can target factor D to prevent both intravascular and extravascular hemolysis in PNH. Pelecopan also be used for other alternative pathway (AP) mediated diseases ^{[1][2][3]} . |
| IC ₅₀ & Target | IC ₅₀ : 14.3 nM (complement factor D) ^[1] |
| In Vitro | Pelecopan has a potent, highly specific inhibitory activity for purified human factor D with an IC ₅₀ value of 14.3 nM and also inhibits its proteolytic activity against factor B bound to C3b with an IC ₅₀ of 28.1 nM ^[1] . |

Pelecopan completely blocks hemolysis of PNH cells in vitro (with an IC₅₀ value of 29.5 nM in rabbit erythrocytes) and suppresses the accumulation of C3 fragments on PNH erythrocytes^[1].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

- [1]. International Nonproprietary Names for Pharmaceutical Substances (INN)
- [2]. AustinKulasekararajMD MRCP, FRCPath, et al. BCX9930, a Potent, Selective, Oral Factor D Inhibitor, Demonstrates Proof-of-Concept As Monotherapy in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH). *Blood* (2020) Volume 136, Supplement 1, 5 November 2
- [3]. XilinChenMDPhD, et al. Preclinical Characterization of BCX9930, a Potent Oral Complement Factor D Inhibitor, Targeting Alternative Pathway-Mediated Diseases Including Paroxysmal Nocturnal Hemoglobinuria (PNH). *Blood* (2020) Volume 136, Supplement 1, 5 Nove
-

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA